---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-011122"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2022-03-21T23:59:59+00:00"
generated_at: "2026-06-26T21:28:42.353659+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Graphite Bio reports FY2021 net loss $70.8M; GPH101 first patient dosing delayed to H2 2022

## Summary
- Cash, equivalents, restricted cash $378.7M as of Dec 31, 2021; runway into Q4 2024.
- FY2021 net loss $70.8M ($2.45/share); Q4 net loss $18.9M ($0.35/share).
- GPH101 Phase 1/2 CEDAR trial: first patient dosing now H2 2022 (COVID-19 impact); initial data 2023.
- New programs: GPH102 for beta-thalassemia (IND mid-2024) and early AAT deficiency program.
- Appointed Alethia Young as CFO, Christine Garrett as Chief of Staff/SVP Ops; promoted Julia Tran to CPO.

## SEC filing metadata
- accession: 0001564590-22-011122
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2022-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000156459022011122/0001564590-22-011122-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000156459022011122/grph-8k_20220321.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-011122
- JSON: https://secwatch.observer/filing/0001564590-22-011122.json
- Plain text: https://secwatch.observer/filing/0001564590-22-011122.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.